Defining Diffuse Large B-Cell Lymphoma Immunotypes by CD8+ T Cells and Natural Killer Cells

Figure 2

Identification of immune subtypes in the diffuse large B-cell lymphoma (DLBCL) cohorts. (a) The calculated hazard ratios and values of immune cells among DLBCL training cohorts (GSE11318, GSE21846, GSE23501, GSE32819, TCGA-DLBCL, and their merged cohort). (b) The correlation value of natural killer cells and activated CD8 T cells in the merged cohort. (c) In the training data sets, the samples were divided into inflamed subtype (IS) and noninflamed subtype (NIS) based on the diagonal line. IS had higher levels of natural killer cells and activated CD8 T cells. (d) Kaplan–Meier curves of OS for patients in the IS and NIS in the training data set. (e) In the testing data set (GSE10846), the samples were divided into the IS and NIS based on the diagonal line. The IS had higher levels of natural killer cells and activated CD8 T cells. (f) Kaplan–Meier curves of OS for patients in IS and NIS in the testing dataset.

(a)

(b)

(c)

(d)

(e)

(f)